Journal
CANCER CELL
Volume 18, Issue 5, Pages 399-400Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2010.10.026
Keywords
-
Categories
Ask authors/readers for more resources
Targeting p53's main negative regulator MDM2 is a promising strategy for treating cancers that retain wildtype p53. Unfortunately, MDM2 inhibitors are largely ineffective against tumors overexpressing MDMX. In this issue of Cancer Cell, Bernal et al. describe a stapled peptide that targets MDMX and suppresses the growth of tumors resistant to MDM2 inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available